BOS172722 + paclitaxel

**BOS172722 + paclitaxel** is an investigational drug combination consisting of BOS172722, a selective and potent small-molecule inhibitor of the spindle assembly checkpoint kinase MPS1 (also known as TTK), and paclitaxel, a microtubule-stabilizing chemotherapeutic agent. BOS172722 impairs the spindle assembly checkpoint, enhancing chromosomal missegregation and cell death, particularly in highly proliferative triple-negative breast cancer (TNBC) cells. When combined with paclitaxel—which induces mitotic arrest—BOS172722 rapidly abrogates the delay in mitosis, leading to gross chromosomal abnormalities and apoptosis. This combination has shown robust in vivo synergy, resulting in significant tumor regression in TNBC xenograft models, including patient-derived models. The current development focus is on TNBC with high unmet need, leveraging the synergistic mechanism of MPS1 inhibition and microtubule disruption[1][3][4][5].

Other names

BOS-172722 + paclitaxel